Guest content from Turner Investment Partners‘ Heather Flick McMeekin, Frank Sustersic, Vijay Shankaran, and Theresa Hoang:
Contract research helps keep drug pipeline flowing
Imagine a new-product development process that typically lasts 10 to 15 years, has only a one in 5,000 chance of succeeding, and costs at least $800 million. That’s the daunting reality that biopharmaceutical companies [...]
460 pages
Hardcover:978-09734676-5-9
Hardcover:978-09734676-6-6
Third Edition
August, 2008
Homepage
Building Biotechnology
Business, Regulations, Patents, Law, Politics, Science
The definitive primer and leading textbook on the business of biotechnology is now available in its third edition. This new edition is over 100 pages longer than the second edition and adds new chapters, new figures and tables, and additional case examples.
Building Biotechnology [...]
Here’s a slideshow of a talk I recently gave at the Johns Hopkins biotechnology MS/MBA program. The purpose is to illustrate the elements which are important to consider after penning your business plan, and to help position oneself to be prepared for unexpected risks.
The material is largely drawn from my book, Building Biotechnology. Go ahead [...]
Courtesy of DrugPatentWatch.com:
Drug Patent Expirations in August 2008
*Drugs may be covered by multiple patents
Tradename
Applicant
Generic Name
Patent Number
Patent Expiration
ADVAIR DISKUS 100/50
Glaxosmithkline
fluticasone propionate; salmeterol xinafoate
4,992,474
Aug 12, 2008
ADVAIR DISKUS 100/50
Glaxosmithkline
fluticasone propionate; salmeterol xinafoate
5,126,375
Aug 12, 2008
ADVAIR DISKUS 100/50
Glaxosmithkline
fluticasone propionate; salmeterol xinafoate
5,225,445
Aug 12, 2008
ADVAIR DISKUS 250/50
Glaxosmithkline
fluticasone propionate; salmeterol xinafoate
4,992,474
Aug 12, 2008
ADVAIR DISKUS 250/50
Glaxosmithkline
fluticasone propionate; salmeterol xinafoate
5,126,375
Aug 12, 2008
ADVAIR DISKUS 250/50
Glaxosmithkline
fluticasone propionate; [...]